Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

2001189 citationsJournal Article

Authors

Tate Thigpen · Gynecologic Oncology Group

Mark F. Brady · Gynecologic Oncology Group

Howard D. Homesley · Gynecologic Oncology Group

John T. Soper · Gynecologic Oncology Group

Jeffrey G. Bell · Gynecologic Oncology Group

Abstract

Tamoxifen demonstrated modest activity at best against endometrial carcinoma and does not warrant further investigation as a single agent for this disease. Ongoing trials will assess the sequential use of tamoxifen and progestational agents.

Topics & Keywords

Endometrial and Cervical Cancer Treatments Lymphoma Diagnosis and Treatment Ovarian cancer diagnosis and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 19, Issue 2, pp. 364-367

DOI: 10.1200/jco.2001.19.2.364

Field-Weighted Citation Impact: 7.99